المؤلفون: Diederik M. Somford, Reindert J.A. van Moorselaar, Carin A. Uyl-de Groot, Ronald de Wit, Laurent M.C.L. Fossion, Niven Mehra, Hans M. Westgeest, Addy C. M. van de Luijtgaarden, Juleon L.L.M. Coenen, N.I. Weijl, Maud M. Geenen, Winald R. Gerritsen, Agnes J. van de Wouw, A.C.M. van den Bergh, Mathijs P. Hendriks, Marco B. Polee, Alphonsus J. M. van den Eertwegh, Andre M. Bergman, Malou C.P. Kuppen, Inge M. van Oort, Daan ten Bokkel Huinink

المساهمون: Guided Treatment in Optimal Selected Cancer Patients (GUTS), Health Technology Assessment (HTA), Medical oncology, Urology, CCA - Cancer Treatment and quality of life, Internal medicine

المصدر: European urology oncology, 4(4), 618-627. De Tijdstroom/Elsevier
European Urology Oncology, 4, 618-627
European urology oncology, 4, 618-627. Elsevier
Kuppen, M C P, Westgeest, H M, van den Eertwegh, A J M, van Moorselaar, R J A, van Oort, I M, Coenen, J L L M, van den Bergh, A C M F, Mehra, N, Somford, D M, Bergman, A M, Ten Bokkel Huinink, D, Fossion, L, Geenen, M M, Hendriks, M P, van de Luijtgaarden, A C M, Polee, M B, Weijl, N I, van de Wouw, A J, de Wit, R, Uyl-de Groot, C A & Gerritsen, W R 2021, ' Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer : Results from the Dutch Castration-resistant Prostate Cancer Registry ', European Urology Oncology, vol. 4, no. 4, pp. 618-627 . https://doi.org/10.1016/j.euo.2019.09.005
European Urology Oncology, 4, 4, pp. 618-627
European Urology Oncology, 4(4), 618-627. Elsevier BV

مصطلحات موضوعية: Oncology, Male, ANTITUMOR-ACTIVITY, 030232 urology & nephrology, chemistry.chemical_compound, Prostate cancer, 0302 clinical medicine, Prednisone, Medicine, Sequencing, Registries, Castration-resistant prostate cancer, DOCETAXEL, Abiraterone acetate, TIME, Prostatic Neoplasms, Castration-Resistant, TRIALS, Docetaxel, Pharmaceutical Preparations, Cabazitaxel, 030220 oncology & carcinogenesis, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], Androgens, Cross resistance, medicine.drug, medicine.medical_specialty, CLINICAL-OUTCOMES, ENZALUTAMIDE, Urology, INCREASED SURVIVAL, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Antigen, SDG 3 - Good Health and Well-being, Internal medicine, Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], Enzalutamide, Humans, Radiology, Nuclear Medicine and imaging, Real-world outcomes, Retrospective Studies, Androgen-receptor targeting agents, business.industry, Androgen Antagonists, medicine.disease, Androgen receptor, chemistry, Surgery, business

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5688ade1d20f2f2f131d73a057ff810
https://research.rug.nl/en/publications/41b16b5e-d8f6-46e7-904f-77d48f068028

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

مصطلحات الفهرس: Castration-resistant prostate cancer, Androgen-receptor targeting agents, info:eu-repo/semantics/article

URL: http://repub.eur.nl/pub/135464